Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

BWXT $   $  
As of . Minimum 20 minute delay.

BWXT Medical has a deep and rich history of radiopharmaceutical innovation, development and manufacturing.  Selected products currently in development include:

    Tc-99m Generators

    BWXT’s scientists and engineers have developed a unique solution to meet the growing demand for medical isotopes needed for diagnostic imaging.Tc-99m Generator Featuring a patent-pending neutron capture process, this innovative technology is designed to produce molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), which is used globally in more than 40 million medical procedures each year.

    What makes our technology different?

    Historically Mo-99 has been produced within research reactors using uranium as a starting material. BWXT’s new proprietary technology features:

    • A neutron capture process which will use molybdenum, rather than uranium, targets (mitigating radioactive waste streams and eliminating nuclear proliferation concerns)
    • Irradiation of molybdenum targets at commercial power reactors.
    • A process to convert low specific activity Mo-99 into technetium generators that perform exactly the same as other generators on the market (i.e. same activity, quality and method of elution)

    After receiving approval, Mo-99 produced at Ontario Power Generation’s Darlington Nuclear Generating Station and in the University of Missouri Research Reactor (MURR) will later be processed at BWXT Medical’s Ottawa facility and incorporated into Tc-99m generators for delivery to radiopharmacies and hospitals across North America.

    In March of 2021, BWXT Medical announced that it had entered into a joint venture with Global Medical Solutions, Ltd. (GMS) to manufacture and distribute radioisotopes and radiopharmaceuticals in the Asia-Pacific. This JV is intending to replicate BWXT Medical’s operations to irradiate molybdenum and manufacture Tc-99m generators in an effort to meet increasing demand in the Asia-Pacific.

    Targeted Therapies

    BWXT Medical is partnering with leading and emerging life science companies to develop and supply products for targeted radionuclide diagnostics and therapies including Actinium-225 (Ac-225), Lutetium-177 (Lu-177), Copper-64 (Cu-64), and Copper-67 (Cu-67).  We announced a partnership with Bayer AG (Bayer) to develop Ac-225, a powerful radioisotope used to deliver alpha radiation directly to tumors either via its bone-seeking properties (radium-223) or by combining alpha radionuclides such as Ac-225 with specific tumor-seeking targeting vectors.

    In the past we have produced a number of isotopes for diagnosis and treatment of disease including:

    • Palladium-103: used to treat early prostate cancer
    • Thallium-201: used in myocardial perfusion imaging
    • Gallium-67: used to detect infection and bronchogenic carcinomas
    • Co-57: radiotracer for vitamin B12 deficiency test
    • Molybdenum-99: used for Tc-99m generators for SPECT scans
    • Iodine-131: used for thyroid imaging, therapy; radiotherapeutic isotope
    • Xenon-133: used as a lung ventilation imaging agent
    • Xenon-127: used for pulmonary ventilation studies
    • Iodine-125: used for brachytherapy
    • Cadmium-109: used for source calibration
    • Copper-64: used in positron emission tomography